Who Paid My Doc
Tyler Reimschisel
Clinical Biochemical Genetics Cleveland, OH Medical Doctor
NPI 1922024223 CMS profile 958998
11100 Euclid Ave, Cleveland, OH 44106
General payments
$35
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$191,918
Through program year 2025, Tyler Reimschisel of Cleveland, OH is reported in the CMS Open Payments database as having received $35 across 1 general payment and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $191,918 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $35 | 1 |
Beside peers
- Tyler Reimschisel
- Clinical Biochemical Genetics median
- Middle half of Clinical Biochemical Genetics
- National median
In program year 2025, general payments to Tyler Reimschisel were reported at $35. Among 23 Clinical Biochemical Genetics profiles paid that year, the median was $237 and the middle half received between $88 and $2,648.
Show as a table
| Year | Tyler Reimschisel | Clinical Biochemical Genetics median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $132 | $20–$1,451 | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | — | — | $132 |
| 2022 | $0 | $157 | $94–$2,848 | $149 |
| 2023 | $0 | $242 | $71–$1,706 | $160 |
| 2024 | $0 | — | — | $164 |
| 2025 | $35 | $237 | $88–$2,648 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 2 drugsPart D claims
25
Drug cost
$1,459,505
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ravicti Glycerol Phenylbutyrate | Brand | 12 | $1,066,019 | |
| Nexviazyme Avalglucosidase Alfa-Ngpt | Brand | 13 | $393,486 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Biochemical Genetics in Ohio
Related records
Clinical Biochemical Genetics in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Biochemical Genetics
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.